StemRIM
Biotechnology company developing regeneration‑inducing therapeutics that pharmacologically mobilize and recruit a patient’s own mesenchymal stem/stromal cells to sites of tissue damage. R&D activities include peptide engineering derived from protein functional domains, ex vivo autologous mesenchymal stromal cell gene‑modified therapies, preclinical in vivo efficacy testing, mechanistic omics studies, and early‑ to mid‑stage clinical development for rare and difficult‑to‑treat diseases.
Industries
Nr. of Employees
medium (51-250)
Patents
Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
US-11969459-B2
View Details
Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
US-11969459-B2
View DetailsProducts
Systemic HMGB1‑derived fragment peptide therapeutic (intravenous)
Synthetic peptide based on a functional fragment of an HMGB1 protein domain intended to mobilize bone‑marrow progenitors into peripheral blood and promote accumulation at sites of tissue injury to enhance regeneration; progressed through non‑clinical models and clinical studies across multiple indications.
Next‑generation systemic regenerative peptide candidates
Artificially designed systemic peptides developed using domain‑focused design and MSC‑induction screening methods to induce endogenous progenitor mobilization and regenerative responses across tissue types.
Locally administered regenerative peptide formulation
Protein/peptide formulation designed for local administration to injured tissue to enhance recruitment and retention of endogenous progenitors in localized lesions.
Autologous MSC‑based ex vivo gene therapy workflow
Autologous mesenchymal stromal cell gene therapy process involving isolation of patient MSCs, ex vivo gene introduction and expansion, and reinfusion to achieve sustained therapeutic gene expression for inherited connective tissue/dermal disorders.
Systemic HMGB1‑derived fragment peptide therapeutic (intravenous)
Synthetic peptide based on a functional fragment of an HMGB1 protein domain intended to mobilize bone‑marrow progenitors into peripheral blood and promote accumulation at sites of tissue injury to enhance regeneration; progressed through non‑clinical models and clinical studies across multiple indications.
Next‑generation systemic regenerative peptide candidates
Artificially designed systemic peptides developed using domain‑focused design and MSC‑induction screening methods to induce endogenous progenitor mobilization and regenerative responses across tissue types.
Locally administered regenerative peptide formulation
Protein/peptide formulation designed for local administration to injured tissue to enhance recruitment and retention of endogenous progenitors in localized lesions.
Autologous MSC‑based ex vivo gene therapy workflow
Autologous mesenchymal stromal cell gene therapy process involving isolation of patient MSCs, ex vivo gene introduction and expansion, and reinfusion to achieve sustained therapeutic gene expression for inherited connective tissue/dermal disorders.
Services
Joint research projects and collaborative research with academic institutions and industry partners using the company’s regeneration‑inducing therapeutic platform and associated IP.
Out‑licensing of development candidates and platform intellectual property under milestone and royalty arrangements.
Joint research projects and collaborative research with academic institutions and industry partners using the company’s regeneration‑inducing therapeutic platform and associated IP.
Out‑licensing of development candidates and platform intellectual property under milestone and royalty arrangements.
Expertise Areas
- Regenerative medicine platform development
- Peptide therapeutic design and engineering
- Mesenchymal stromal cell biology and endogenous mobilization
- Ex vivo autologous MSC gene‑modified therapy development
Key Technologies
- Protein domain mapping and peptide engineering
- Synthetic peptide therapeutic chemistry
- Ex vivo MSC culture and gene modification
- Animal disease models for in vivo efficacy testing
News & Updates
Company investor presentation videos and slide materials including FY2024 and FY2025 financial presentation PDFs and investor briefing recordings.
Patent registration announcements in 2026 covering ex vivo MSC gene therapy and additional indications for peptide therapeutics across jurisdictions.
Announcement of a peer‑reviewed publication relating to epidermal stem cell formation.
Company activities were featured in a government promotional video highlighting regional drug discovery activity.
Media coverage discussing Phase II planning for acute ischemic stroke and other pipeline developments.
Multiple peer‑reviewed papers (2020–2024) reporting preclinical efficacy of HMGB1 fragment‑derived peptides in models of cardiac, hepatic, pulmonary and other disorders.
Company investor presentation videos and slide materials including FY2024 and FY2025 financial presentation PDFs and investor briefing recordings.
Patent registration announcements in 2026 covering ex vivo MSC gene therapy and additional indications for peptide therapeutics across jurisdictions.
Announcement of a peer‑reviewed publication relating to epidermal stem cell formation.
Company activities were featured in a government promotional video highlighting regional drug discovery activity.
Media coverage discussing Phase II planning for acute ischemic stroke and other pipeline developments.
Multiple peer‑reviewed papers (2020–2024) reporting preclinical efficacy of HMGB1 fragment‑derived peptides in models of cardiac, hepatic, pulmonary and other disorders.